Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 24, 2008. The document serves as a replacement for previous announcements issued in April, July, and October 2008 regarding director transactions under the GlaxoSmithKline Performance Share Plan and the SmithKline Beecham Medium Term Incentive Plan.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to correcting administrative details regarding share price calculations for dividend reinvestment plans.
Material Changes
The primary material change disclosed is the correction of market prices for Ordinary share ADRs used to calculate share reinvestments for plan participants:
- April 2008 Dividend: The ADR price was corrected from $43.84 to $43.87.
- October 2008 Dividend: The ADR price was corrected from $35.41 to $37.19.
Consequently, the number of ADRs reinvested for participants has been adjusted. Details regarding former director JP Garnier have been excluded from these replacement announcements.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a procedural notification to ensure compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the accurate reporting of director interests.
Investor Verification Points
- Verify the corrected ADR prices ($43.87 for April and $37.19 for October) against personal dividend reinvestment records if applicable.
- Confirm that the updated share counts for directors D J Phelan and E J Gray reflect the corrected pricing.
- Note that this filing does not impact the company's financial statements or operational outlook.